Developer docs
API playgroundTry for free, no card

Search company profiles

Orexo

Full company profile

uuid0002hqh

Namestring
Orexo
Legal namestring
Orexo AB (publ.)
Websiteurl
orexo.com
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Orexo AB (publ.) is a Swedish specialty pharmaceutical company headquartered in Uppsala that develops improved pharmaceutical treatments using proprietary drug delivery technology, in particular its AmorphOX powder-based platform. Founded in 1995 and listed on Nasdaq Stockholm (ORX) with ADRs on OTCQX (ORXOY), Orexo historically operated a US commercial subsidiary that sold Zubsolv (buprenorphine/naloxone) for opioid use disorder until divesting US rights to Dexcel Pharma USA in December 2025 for $91 million, a transaction that fundamentally repositioned the business.

AmorphOX is the company's core technology asset: a powder-based delivery system that stabilizes amorphous materials — including peptides, proteins, and vaccines — across extreme temperature ranges (-20°C to 70-80°C), eliminating cold-chain requirements and enabling intranasal or oral administration with high bioavailability. The platform underpins an active development pipeline including OX640 (nasal epinephrine for anaphylaxis, entering pivotal studies Q4 2026), OX390 (intranasal atipamezole for reversing xylazine/medetomidine overdoses, preclinical with FDA Type C meeting planned and BARDA support), OX472 (oral semaglutide, patent filed), Izipry (high-dose naloxone rescue medication, NDA resubmission planned Q3 2026 after a Complete Response Letter), and an AmorphOX-based intranasal vaccine program with Abera Bioscience. Orexo has also commercialized Abstral (breakthrough cancer pain), Edluar (insomnia), and Diabact UBT (H. pylori diagnosis) through partners such as Viatris.

Orexo's business model has materially shifted from internalized US commercialization toward a partnership-driven R&D and licensing model. The company now generates minimal product revenue (SEK 5.0 million in Q1 2026 from continuing operations, versus SEK 26.0 million for FY2025), supplemented by non-dilutive government funding (BARDA $8 million for OX390, contract number 75A50125C00010), planned milestone payments from partners, and the strategic intent to monetize AmorphOX through platform out-licensing to other pharmaceutical developers. Customers span patients with opioid use disorder, anaphylaxis, and overdose emergencies; US government agencies (BARDA/HHS) for medical countermeasures; and pharmaceutical partners licensing the AmorphOX technology for their own development programs. The Novo Holdings A/S ownership position since 2010 provides additional capital backing.

Short descriptiontext

Orexo AB is a Swedish specialty pharmaceutical company developing treatments via its proprietary AmorphOX powder-based drug delivery platform, targeting opioid use disorder, anaphylaxis, and emerging overdose threats through R&D partnerships and platform licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersUppsala, Sweden
HQ citystring
Uppsala
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
powder drug delivery, sublingual pharmaceuticals, intranasal medications, rescue medications, specialty pharmaceuticals
Industry3 codes
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLACANAN
DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales (discontinued US commercial operations)
TypeOne Time License
Description

Orexo historically generated revenue from direct sales of Zubsolv in the US market through its commercial subsidiary Orexo US Inc. These commercial operations were divested to Dexcel Pharma USA in December 2025. Going forward, the company earns minimal product revenues (SEK 5.0m in Q1 2026) from residual activities.

orexo.com
2R&D Partnerships and BARDA Contract Revenue
TypeLicensing Royalties
Description

Following the Zubsolv divestment, Orexo is focused on R&D partnerships and BARDA funding. The OX390 program is developed in partnership with BARDA (US Department of Health and Human Services). BARDA awarded USD 8 million for OX390 development. Revenue is project-based from federal funding.

orexo.com
3Zubsolv US Divestment Proceeds
TypeTransaction Fee
Description

Orexo received SEK 91 million from Dexcel Pharma USA for the sale of US rights to Zubsolv in December 2025, providing near-term cash and removing US commercial costs.

marketscreener.com
4Partnering and Licensing (future)
TypeLicensing Royalties
Description

Orexo's strategy involves advancing proprietary development programs toward defined value inflection points with the objective of attracting partnerships for continued development and commercialization. The company also makes AmorphOX technology available to other pharmaceutical companies for use in their own development programs.

orexo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1AmorphOX
Description

Proprietary powder-based drug delivery technology that stabilizes amorphous materials including peptides and biologics, designed for strong bioavailability and next-generation drug development.

orexo.com
Core offering1 text field

Orexo is a Swedish pharmaceutical company that develops and commercializes improved treatments using its proprietary AmorphOX powder-based drug delivery platform, which stabilizes amorphous materials including peptides and biologics to enable rapid intranasal and sublingal absorption. The company's portfolio spans commercialized specialty products (Zubsolv, Abstral, Edluar, Diabact UBT), digital therapeutics (Deprexis, MODIA, Vorvida) and a development pipeline including OX640 nasal epinephrine, OX390 xylazine/medetomidine antidote, OX472 semaglutide, Izipry high-dose naloxone, and intranasal vaccines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Zubsolv US gross sales exceeded USD 1 billion since 2013 launch
+4 more records
Product overview1 text field

Orexo is a Swedish pharmaceutical company focused on drug delivery technology and pharmaceutical product development. The company operates primarily through its proprietary AmorphOX platform, a powder-based drug delivery technology that stabilizes amorphous materials including peptides and biologics, enabling rapid absorption and improved bioavailability. Orexo's product portfolio spans commercialized products (Edluar for insomnia, Abstral for breakthrough cancer pain, Diabact for H. pylori diagnosis), divested products (Zubsolv for opioid use disorder, divested to Dexcel Pharma USA in December 2025), digital therapeutics (Deprexis for depression, MODIA and Vorvida for substance use disorders licensed from GAIA AG), and a development pipeline including OX640 (nasal epinephrine for anaphylaxis), OX390 (antidote for xylazine/medetomidine overdoses with BARDA partnership), OX472 (semaglutide formulations), and Izipry (high-dose naloxone rescue medication). Following the Zubsolv divestment, Orexo has strategically pivoted toward R&D with a focus on advancing its AmorphOX-based pipeline programs.

Product and service13 records
1AmorphOX
CategoryTechnology platform
Description

Proprietary powder-based drug delivery technology platform that stabilizes amorphous materials including peptides and biologics, designed to support strong bioavailability and rapid absorption. Made available to pharmaceutical partners for use in their own development programs covering small molecules, peptides, proteins, and vaccines.

2Zubsolv
CategoryCommercialized pharmaceutical product
Description

Buprenorphine/naloxone sublingual tablet for treatment of opioid use disorder. US commercial rights divested to Dexcel Pharma USA in December 2025 for SEK 91 million; retained in other markets.

3Abstral
CategoryCommercialized pharmaceutical product
Description

Sublingual fentanyl product for treatment of breakthrough cancer pain. Approved in first market in 2008 and commercialized worldwide through partners.

4Edluar
CategoryCommercialized pharmaceutical product
Description

Sublingual zolpidem product for treatment of insomnia. Approved in 2009 and commercialized by Viatris on multiple markets.

5Diabact UBT
CategoryCommercialized diagnostic product
Description

Urea breath test product for diagnosing Helicobacter pylori infection. First market approval received in 2000 and commercialized worldwide through partners.

6OX640
CategoryPipeline pharmaceutical product
Description

Powder-based nasal epinephrine medication for treatment of severe allergic reactions and anaphylaxis using AmorphOX technology. Designed to provide rapid delivery with strong temperature stability and is being advanced toward pivotal clinical studies.

7OX390
CategoryPipeline pharmaceutical product
Description

Emergency intranasal powder treatment containing atipamezole to reverse overdoses involving xylazine and medetomidine (alpha-2 agonists). Developed in partnership with BARDA for community-based use by first responders and laypersons.

8OX472
CategoryPipeline pharmaceutical product
Description

AmorphOX-based exploratory program developing semaglutide formulations via nasal and oral delivery routes, with formulation development initiated for semaglutide tablets.

9Izipry
CategoryPipeline pharmaceutical product
Description

High-dose naloxone rescue medication for opioid overdoses using AmorphOX-based formulation. NDA resubmission planned for Q3 2026 with intended commercialization through partnering strategy.

10OX-MPI Vaccine
CategoryPipeline vaccine product
Description

Powder-based intranasal vaccine formulated with AmorphOX technology, developed in collaboration with Abera Bioscience. Demonstrated positive data from in-vivo study in 2025.

11Deprexis
CategoryDigital therapeutic
Description

Scientifically proven digital support program for depression developed by partner GAIA AG. Multiple clinical trials have demonstrated its efficacy.

12MODIA
CategoryDigital therapeutic
Description

Digital support program for the treatment of opioid use disorder developed in partnership with GAIA AG, designed to support patients with OUD alongside medication-based treatment.

13Vorvida
CategoryDigital therapeutic
Description

Scientifically proven digital therapy for alcohol misuse including alcohol use disorder. Orexo acquired US rights from GAIA AG.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Royal Swedish Academy of Engineering Sciences (IVA)
Strategic tierMinorTypeOthersAnnounced on2026-03-06
Description

The Royal Swedish Academy of Engineering Sciences (IVA) in Stockholm served as the venue for Orexo's R&D Day on March 24, 2026, where the company presented its updated strategy following the Zubsolv divestment, focusing on AmorphOX and pipeline programs.

orexo.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-22
Description

Dexcel Pharma USA acquired all US rights to Zubsolv and the associated commercial infrastructure (sales force, distribution, inventory) through an Asset Purchase Agreement. The transaction closed on January 2, 2026, with Dexcel assuming full responsibility for US commercialization of Zubsolv for opioid use disorder.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

BARDA, part of the US Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response, awarded Orexo US Inc. USD 8 million to support the development of OX390 as a medical countermeasure against threats from xylazine and medetomidine. OX390 is being developed as a rapidly acting intranasal powder using AmorphOX technology. BARDA funding is under contract number 75A50125C00010. The program aims to address the rising threat of alpha-2 agonist adulterants in the US illicit drug supply.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

GAIA AG is a world leader in digital therapeutics. Orexo partnered with GAIA AG in 2019 to develop MODIA, a digital support program for opioid use disorder. Orexo also acquired US rights for Vorvida, a digital therapy for alcohol misuse including AUD, and owns US rights for Deprexis, a digital therapy for depression developed by GAIA. In 2024, US commercial rights to Deprexis were returned to GAIA AG. Orexo is exploring business development opportunities with GAIA for remaining digital therapeutic assets.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-29
Description

Collaboration with Abera Bioscience for the development of a powder-based intranasal vaccine formulated with AmorphOX technology. Positive data obtained from an in-vivo study demonstrating viability of the approach in 2025.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Global specialty pharma network; comparable as the broader commercialization/distribution backdrop behind Dexcel Pharma USA, which now owns US Zubsolv rights. Indirectly connected as Orexo's US commercialization counterparty going forward.

TypeDirect peer
Description

Specialty pharmaceutical company focused on injectable, inhalation, and intranasal products including epinephrine and naloxone - directly comparable product overlap with OX640 and Izipry. Comparable size and commercialization approach via specialty channels.

TypeDirect peer
Description

Biotech whose ENHANZE drug delivery platform enables subcutaneous delivery of biologics via proprietary enzyme technology and licenses it broadly to large pharma. Highly comparable business model: a single proprietary delivery platform driving partnership/licensing revenue across multiple partners.

TypeDirect peer
Description

Smaller specialty pharmaceutical company with a mix of legacy commercial products and pipeline assets, similar size range and surgical focus on US specialty commercialization prior to Orexo's Zubsolv divestment.

TypeDirect peer
Description

Specialty CDMO and drug delivery company with deep expertise in particle engineering, amorphous solid dispersions, and nasal/inhaled formulations - directly comparable to AmorphOX's amorphous stabilization approach for small molecules and peptides.

TypeDirect peer
Description

Specialty biopharmaceutical company focused on medical countermeasures and rescue products including NARCAN (naloxone nasal spray) and other emergency-use pharmaceuticals. Direct overlap with Orexo's rescue-medicine focus (OX390, Izipry, OX640) and BARDA-style government procurement exposure.

TypeEmerging player
Description

Specialty pharma focused on intranasal epinephrine (Neffy, FDA-approved 2024) - direct head-to-head comparable for OX640 in the needle-free epinephrine segment. Like Orexo, targets the same underserved population with a nasal product.

TypeBroad incumbent
Description

Global leading contract development and manufacturing organization (CDMO) with extensive drug delivery capabilities including oral, inhalation, and nasal formulation services. Comparable to Orexo as a drug delivery technology/partnering organization serving pharma companies across multiple dosage forms.

TypeDirect peer
Description

Swedish specialty pharmaceutical company based in Lund with a proprietary drug delivery technology (FluidCrystal) used to formulate long-acting injectables and other formulations. Highly comparable to Orexo: similar Swedish origin, comparable size and headcount, advanced drug delivery platform, focus on specialty therapeutics and partnerships, public listing.

TypeDirect peer
Description

Specialty pharmaceutical company focused on responsible pain management including opioid and ADHD products; comparable to Orexo's specialty-pharma model, comparable size, and overlap with Zubsolv's opioid use disorder space prior to divestment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orexo

Specialty Pharmaceuticalsorexo.com

Orexo AB is a Swedish specialty pharmaceutical company developing treatments via its proprietary AmorphOX powder-based drug delivery platform, targeting opioid use disorder, anaphylaxis, and emerging overdose threats through R&D partnerships and platform licensing.

What Orexo does

Orexo AB (publ.) is a Swedish specialty pharmaceutical company headquartered in Uppsala that develops improved pharmaceutical treatments using proprietary drug delivery technology, in particular its AmorphOX powder-based platform. Founded in 1995 and listed on Nasdaq Stockholm (ORX) with ADRs on OTCQX (ORXOY), Orexo historically operated a US commercial subsidiary that sold Zubsolv (buprenorphine/naloxone) for opioid use disorder until divesting US rights to Dexcel Pharma USA in December 2025 for $91 million, a transaction that fundamentally repositioned the business.

AmorphOX is the company's core technology asset: a powder-based delivery system that stabilizes amorphous materials — including peptides, proteins, and vaccines — across extreme temperature ranges (-20°C to 70-80°C), eliminating cold-chain requirements and enabling intranasal or oral administration with high bioavailability. The platform underpins an active development pipeline including OX640 (nasal epinephrine for anaphylaxis, entering pivotal studies Q4 2026), OX390 (intranasal atipamezole for reversing xylazine/medetomidine overdoses, preclinical with FDA Type C meeting planned and BARDA support), OX472 (oral semaglutide, patent filed), Izipry (high-dose naloxone rescue medication, NDA resubmission planned Q3 2026 after a Complete Response Letter), and an AmorphOX-based intranasal vaccine program with Abera Bioscience. Orexo has also commercialized Abstral (breakthrough cancer pain), Edluar (insomnia), and Diabact UBT (H. pylori diagnosis) through partners such as Viatris.

Orexo's business model has materially shifted from internalized US commercialization toward a partnership-driven R&D and licensing model. The company now generates minimal product revenue (SEK 5.0 million in Q1 2026 from continuing operations, versus SEK 26.0 million for FY2025), supplemented by non-dilutive government funding (BARDA $8 million for OX390, contract number 75A50125C00010), planned milestone payments from partners, and the strategic intent to monetize AmorphOX through platform out-licensing to other pharmaceutical developers. Customers span patients with opioid use disorder, anaphylaxis, and overdose emergencies; US government agencies (BARDA/HHS) for medical countermeasures; and pharmaceutical partners licensing the AmorphOX technology for their own development programs. The Novo Holdings A/S ownership position since 2010 provides additional capital backing.

Orexo firmographics

Firmographics
Name
Orexo
Legal name
Orexo AB (publ.)
Website
https://orexo.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
51–100 employees
Short description
Orexo AB is a Swedish specialty pharmaceutical company developing treatments via its proprietary AmorphOX powder-based drug delivery platform, targeting opioid use disorder, anaphylaxis, and emerging overdose threats through R&D partnerships and platform licensing.
Ownership category
akta.pro rank

Orexo industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLACANAN
DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Powder drug delivery
  • Sublingual pharmaceuticals
  • Intranasal medications
  • Rescue medications
  • Specialty pharmaceuticals

Where Orexo is headquartered

Location

Headquarters

HQ city
Uppsala
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Orexo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Sales (discontinued US commercial operations): Orexo historically generated revenue from direct sales of Zubsolv in the US market through its commercial subsidiary Orexo US Inc. These commercial operations were divested to Dexcel Pharma USA in December 2025. Going forward, the company earns minimal product revenues (SEK 5.0m in Q1 2026) from residual activities.
  2. R&D Partnerships and BARDA Contract Revenue: Following the Zubsolv divestment, Orexo is focused on R&D partnerships and BARDA funding. The OX390 program is developed in partnership with BARDA (US Department of Health and Human Services). BARDA awarded USD 8 million for OX390 development. Revenue is project-based from federal funding.
  3. Zubsolv US Divestment Proceeds: Orexo received SEK 91 million from Dexcel Pharma USA for the sale of US rights to Zubsolv in December 2025, providing near-term cash and removing US commercial costs.
  4. Partnering and Licensing (future): Orexo's strategy involves advancing proprietary development programs toward defined value inflection points with the objective of attracting partnerships for continued development and commercialization. The company also makes AmorphOX technology available to other pharmaceutical companies for use in their own development programs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Orexo product offering

Product offering

Core offering

Orexo is a Swedish pharmaceutical company that develops and commercializes improved treatments using its proprietary AmorphOX powder-based drug delivery platform, which stabilizes amorphous materials including peptides and biologics to enable rapid intranasal and sublingal absorption. The company's portfolio spans commercialized specialty products (Zubsolv, Abstral, Edluar, Diabact UBT), digital therapeutics (Deprexis, MODIA, Vorvida) and a development pipeline including OX640 nasal epinephrine, OX390 xylazine/medetomidine antidote, OX472 semaglutide, Izipry high-dose naloxone, and intranasal vaccines.

Product overview

Orexo is a Swedish pharmaceutical company focused on drug delivery technology and pharmaceutical product development. The company operates primarily through its proprietary AmorphOX platform, a powder-based drug delivery technology that stabilizes amorphous materials including peptides and biologics, enabling rapid absorption and improved bioavailability. Orexo's product portfolio spans commercialized products (Edluar for insomnia, Abstral for breakthrough cancer pain, Diabact for H. pylori diagnosis), divested products (Zubsolv for opioid use disorder, divested to Dexcel Pharma USA in December 2025), digital therapeutics (Deprexis for depression, MODIA and Vorvida for substance use disorders licensed from GAIA AG), and a development pipeline including OX640 (nasal epinephrine for anaphylaxis), OX390 (antidote for xylazine/medetomidine overdoses with BARDA partnership), OX472 (semaglutide formulations), and Izipry (high-dose naloxone rescue medication). Following the Zubsolv divestment, Orexo has strategically pivoted toward R&D with a focus on advancing its AmorphOX-based pipeline programs.

Differentiator

Problem solved

Functional benefit

Brands

  • AmorphOX: Proprietary powder-based drug delivery technology that stabilizes amorphous materials including peptides and biologics, designed for strong bioavailability and next-generation drug development.

Products and services

  • AmorphOX Proprietary powder-based drug delivery technology platform that stabilizes amorphous materials including peptides and biologics, designed to support strong bioavailability and rapid absorption. Made available to pharmaceutical partners for use in their own development programs covering small molecules, peptides, proteins, and vaccines.
  • Zubsolv Buprenorphine/naloxone sublingual tablet for treatment of opioid use disorder. US commercial rights divested to Dexcel Pharma USA in December 2025 for SEK 91 million; retained in other markets.
  • Abstral Sublingual fentanyl product for treatment of breakthrough cancer pain. Approved in first market in 2008 and commercialized worldwide through partners.
  • Edluar Sublingual zolpidem product for treatment of insomnia. Approved in 2009 and commercialized by Viatris on multiple markets.
  • Diabact UBT Urea breath test product for diagnosing Helicobacter pylori infection. First market approval received in 2000 and commercialized worldwide through partners.
  • OX640 Powder-based nasal epinephrine medication for treatment of severe allergic reactions and anaphylaxis using AmorphOX technology. Designed to provide rapid delivery with strong temperature stability and is being advanced toward pivotal clinical studies.
  • OX390 Emergency intranasal powder treatment containing atipamezole to reverse overdoses involving xylazine and medetomidine (alpha-2 agonists). Developed in partnership with BARDA for community-based use by first responders and laypersons.
  • OX472 AmorphOX-based exploratory program developing semaglutide formulations via nasal and oral delivery routes, with formulation development initiated for semaglutide tablets.
  • Izipry High-dose naloxone rescue medication for opioid overdoses using AmorphOX-based formulation. NDA resubmission planned for Q3 2026 with intended commercialization through partnering strategy.
  • OX-MPI Vaccine Powder-based intranasal vaccine formulated with AmorphOX technology, developed in collaboration with Abera Bioscience. Demonstrated positive data from in-vivo study in 2025.
  • Deprexis Scientifically proven digital support program for depression developed by partner GAIA AG. Multiple clinical trials have demonstrated its efficacy.
  • MODIA Digital support program for the treatment of opioid use disorder developed in partnership with GAIA AG, designed to support patients with OUD alongside medication-based treatment.
  • Vorvida Scientifically proven digital therapy for alcohol misuse including alcohol use disorder. Orexo acquired US rights from GAIA AG.

Quantifiable outcome

  • Zubsolv US gross sales exceeded USD 1 billion since 2013 launch
  • +4 more outcomes

Companies that use Orexo

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Orexo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Orexo partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Royal Swedish Academy of Engineering Sciences (IVA)minorOthers · 6 March 2026The Royal Swedish Academy of Engineering Sciences (IVA) in Stockholm served as the venue for Orexo's R&D Day on March 24, 2026, where the company presented its updated strategy following the Zubsolv divestment, focusing on AmorphOX and pipeline programs.
  • Dexcel Pharma USAcoreChannel Partner/ Reseller/ Distributor · 22 December 2025Dexcel Pharma USA acquired all US rights to Zubsolv and the associated commercial infrastructure (sales force, distribution, inventory) through an Asset Purchase Agreement. The transaction closed on January 2, 2026, with Dexcel assuming full responsibility for US commercialization of Zubsolv for opioid use disorder.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 29 September 2025BARDA, part of the US Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response, awarded Orexo US Inc. USD 8 million to support the development of OX390 as a medical countermeasure against threats from xylazine and medetomidine. OX390 is being developed as a rapidly acting intranasal powder using AmorphOX technology. BARDA funding is under contract number 75A50125C00010. The program aims to address the rising threat of alpha-2 agonist adulterants in the US illicit drug supply.
  • GAIA AGcoreStrategic or Co-development Partner · 29 September 2025GAIA AG is a world leader in digital therapeutics. Orexo partnered with GAIA AG in 2019 to develop MODIA, a digital support program for opioid use disorder. Orexo also acquired US rights for Vorvida, a digital therapy for alcohol misuse including AUD, and owns US rights for Deprexis, a digital therapy for depression developed by GAIA. In 2024, US commercial rights to Deprexis were returned to GAIA AG. Orexo is exploring business development opportunities with GAIA for remaining digital therapeutic assets.
  • Abera BioscienceminorStrategic or Co-development Partner · 29 September 2025Collaboration with Abera Bioscience for the development of a powder-based intranasal vaccine formulated with AmorphOX technology. Positive data obtained from an in-vivo study demonstrating viability of the approach in 2025.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Orexo competitors and assessment

Company assessment

Others

  • Mundipharma (Dexcel Pharma related): Global specialty pharma network; comparable as the broader commercialization/distribution backdrop behind Dexcel Pharma USA, which now owns US Zubsolv rights. Indirectly connected as Orexo's US commercialization counterparty going forward.

Direct peers

  • Amphastar Pharmaceuticals: Specialty pharmaceutical company focused on injectable, inhalation, and intranasal products including epinephrine and naloxone - directly comparable product overlap with OX640 and Izipry. Comparable size and commercialization approach via specialty channels.
  • Halozyme Therapeutics: Biotech whose ENHANZE drug delivery platform enables subcutaneous delivery of biologics via proprietary enzyme technology and licenses it broadly to large pharma. Highly comparable business model: a single proprietary delivery platform driving partnership/licensing revenue across multiple partners.
  • Acorda Therapeutics: Smaller specialty pharmaceutical company with a mix of legacy commercial products and pipeline assets, similar size range and surgical focus on US specialty commercialization prior to Orexo's Zubsolv divestment.
  • Hovione: Specialty CDMO and drug delivery company with deep expertise in particle engineering, amorphous solid dispersions, and nasal/inhaled formulations - directly comparable to AmorphOX's amorphous stabilization approach for small molecules and peptides.
  • Emergent BioSolutions: Specialty biopharmaceutical company focused on medical countermeasures and rescue products including NARCAN (naloxone nasal spray) and other emergency-use pharmaceuticals. Direct overlap with Orexo's rescue-medicine focus (OX390, Izipry, OX640) and BARDA-style government procurement exposure.
  • Camurus: Swedish specialty pharmaceutical company based in Lund with a proprietary drug delivery technology (FluidCrystal) used to formulate long-acting injectables and other formulations. Highly comparable to Orexo: similar Swedish origin, comparable size and headcount, advanced drug delivery platform, focus on specialty therapeutics and partnerships, public listing.
  • Collegium Pharmaceutical: Specialty pharmaceutical company focused on responsible pain management including opioid and ADHD products; comparable to Orexo's specialty-pharma model, comparable size, and overlap with Zubsolv's opioid use disorder space prior to divestment.

Emerging players

  • ARS Pharmaceuticals: Specialty pharma focused on intranasal epinephrine (Neffy, FDA-approved 2024) - direct head-to-head comparable for OX640 in the needle-free epinephrine segment. Like Orexo, targets the same underserved population with a nasal product.

Broad incumbents

  • Catalent: Global leading contract development and manufacturing organization (CDMO) with extensive drug delivery capabilities including oral, inhalation, and nasal formulation services. Comparable to Orexo as a drug delivery technology/partnering organization serving pharma companies across multiple dosage forms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Orexo social profiles

Digital presence

Orexo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orexo leadership team

Management profile

Number of profiles

Profiles12 records

Orexo subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Orexo funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orexo M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orexo

What does Orexo do?

Orexo is a Swedish pharmaceutical company that develops and commercializes improved treatments using its proprietary AmorphOX powder-based drug delivery platform, which stabilizes amorphous materials including peptides and biologics to enable rapid intranasal and sublingal absorption. The company's portfolio spans commercialized specialty products (Zubsolv, Abstral, Edluar, Diabact UBT), digital therapeutics (Deprexis, MODIA, Vorvida) and a development pipeline including OX640 nasal epinephrine, OX390 xylazine/medetomidine antidote, OX472 semaglutide, Izipry high-dose naloxone, and intranasal vaccines.

Is Orexo a public or private company?

Orexo is a public company. It is classified as public and is currently operating.

When was Orexo founded?

Orexo was founded in 1995. It employs 51 to 100 people.

Where is Orexo based?

Orexo is headquartered in Uppsala, Sweden, in the Europe region.

How does Orexo make money?

Four revenue lines are on record. Product Sales (discontinued US commercial operations) is the primary driver. The others are R&D Partnerships and BARDA Contract Revenue, zubsolv US Divestment Proceeds and partnering and Licensing (future).

Who are Orexo's main competitors?

Mundipharma (Dexcel Pharma related) is listed as an others. Direct peers are Amphastar Pharmaceuticals, Halozyme Therapeutics, Acorda Therapeutics, Hovione, Emergent BioSolutions, Camurus and Collegium Pharmaceutical. ARS Pharmaceuticals is listed as an emerging player. Catalent is listed as a broad incumbent.

Does Orexo have an API?

No public API is recorded for Orexo.

What industry is Orexo in?

Orexo's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLACANAN, DTx/SaMD Regulatory, Quality & Compliance Software (QMS/ISO/FDA). Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AffarsvarldenOrexo: Okända undergaranter kan komma att äga majoritetenOrexo's share issuance is 69.2% secured via commitments and a guarantee, with underguarantors potentially owning 78% after the deal. The company has not disclosed the underguarantors' identities, and the issuance is expected to cost about 30 Mkr. The underguarantors' names remain undisclosed.MarketScreenerOrexo presents new data for OX640, showing rapid absorption and high stabilityOrexo presented new data for its nasal epinephrine powder OX640 at the ACAAI allergy congress, showing rapid absorption in allergic rhinitis. After one year of accelerated aging, OX640 retained over 98% of its R-epinephrine content, compared with 55% for an autoinjector and 66% for a liquid nasal spray. The drug is being developed for anaphylaxis treatment.News-MedicalOrexo and SVF Vaccines collaborate to explore AmorphOX® formulation of LNP-mRNA vaccinesOrexo AB and SVF Vaccines announced a collaboration to test Orexo's AmorphOX powder technology for stable LNP-mRNA vaccine formulations. The project aims to preserve nanoparticle integrity and mRNA activity, with potential for intranasal administration. Results will guide further development and expansion of the collaboration.The future of tradingKDventures portfolio company SVF Vaccines partners with Orexo to explore powder-based mRNA vaccinesSVF Vaccines, a KDventures portfolio company, entered a research collaboration with Orexo to explore stable powder-based mRNA vaccine formulations. The partnership will test Orexo's AmorphOX technology for spray-drying lipid nanoparticle-encapsulated mRNA, with initial in vitro feasibility studies planned.The future of tradingKDventures' SVF Vaccines Collaborates With OrexoKDventures' SVF Vaccines has entered a research collaboration with Orexo on powder-based LNP-mRNA vaccines. The company states that stable powder-based formulations could enable alternative administration routes for mRNA vaccines.TradingViewKDventures (KDV_B) Portfolio Company Starts Exploratory mRNA Formulation StudySVF Vaccines and Orexo will test whether AmorphOX can produce stable powder-based LNP-mRNA formulations, with an initial in vitro feasibility phase. Further development depends on results, and no financial terms or commercial impact are disclosed. KDventures owns 33% of SVF Vaccines.MarketScreenerOrexo launches research collaboration with SVF Vaccines on mRNA vaccinesOrexo is collaborating with SVF Vaccines to test its AmorphOX technology for spray-drying mRNA vaccines. The collaboration aims to develop stable, powder-based vaccines that could improve storage and enable needle-free nasal administration. Results will guide further development and potential expansion.MarketScreenerOrexo presents new OX640 data at US medical congressOrexo will present additional data on OX640, its nasal epinephrine powder, at the American College of Allergy, Asthma & Immunology's annual congress in Phoenix on November 12-16. The data show the powder quickly reaches clinically relevant epinephrine levels and maintains stability under accelerated aging conditions.TradingViewOrexo AB (publ) (ORX) Shareholders Approve Rights IssueOrexo AB's EGM approved a rights issue of ordinary shares with preferential rights. Proceeds will strengthen financial position, fund development, cover a share of an expected DOJ settlement, and bolster working capital. The record date is Nov 10, 2026, with subscription Nov 12–26, 2026.TradingViewReport from Orexo AB’s extraordinary general meeting, 6 November 2026Orexo's extraordinary general meeting on 6 November 2026 approved a rights issue of ordinary shares with preferential rights, to strengthen finances and fund development and a DOJ settlement. The record date is 10 November 2026, with subscription from 12 to 26 November 2026. The meeting also amended articles of association and authorized underwriting fees.